Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Juni 2016 17:35 ET | Quelle: ApeX Therapeutics, Inc.

ApeX Therapeutics Files IND to Initiate Phase 1 Study to Evaluate the Tolerability and Anti-Tumor Effects of APX3330

INDIANAPOLIS, IN--(Marketwired - June 20, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced the filing of an Investigation New...
12. Mai 2016 16:00 ET | Quelle: Apex Therapeutics, Inc.

ApeX Therapeutics and Researchers at Indiana University to Present Phase 1 Clinical Plan for APX3330 and Novel Approach to Addressing Therapeutic Resistance at AACR Pancreatic Cancer Meeting

INDIANAPOLIS, IN--(Marketwired - May 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, in collaboration with researchers at Indiana...
12. April 2016 08:00 ET | Quelle: Apex Therapeutics, Inc.

ApeX Therapeutics to Present Ability of APX3330 to Target Multiple Oncogenic Transcription Factors in Pancreatic Cancer as Single Agent or Combination Therapy at AACR Annual Meeting

INDIANAPOLIS, IN--(Marketwired - April 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced three poster presentations...

Vorherige Seite